img

Global Omalizumab Biosimilars Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Omalizumab Biosimilars Market Insights, Forecast to 2034

Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Global Omalizumab Biosimilars market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Omalizumab Biosimilars industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Omalizumab Biosimilars market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Omalizumab Biosimilars market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Roche
Novartis
Glenmark Pharmaceuticals
Selexis
Generium
CuraTeQ
Celltrion Healthcare
Alvotech
BiosanaPharma
Mabpharm
CSPC Pharmaceutical Group
Biomabs
HisunPharm
Segment by Type
150 mg/mL
75 mg/0.5 mL

Segment by Application


Persistent Asthma
Nasal Polyps
Chronic Idiopathic Urticaria

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Omalizumab Biosimilars plant distribution, commercial date of Omalizumab Biosimilars, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Omalizumab Biosimilars introduction, etc. Omalizumab Biosimilars Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Omalizumab Biosimilars
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Omalizumab Biosimilars Product Introduction
1.2 Market by Type
1.2.1 Global Omalizumab Biosimilars Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 150 mg/mL
1.2.3 75 mg/0.5 mL
1.3 Market by Application
1.3.1 Global Omalizumab Biosimilars Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Persistent Asthma
1.3.3 Nasal Polyps
1.3.4 Chronic Idiopathic Urticaria
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Omalizumab Biosimilars Sales Estimates and Forecasts 2018-2029
2.2 Global Omalizumab Biosimilars Revenue by Region
2.2.1 Global Omalizumab Biosimilars Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Omalizumab Biosimilars Revenue by Region (2018-2024)
2.2.3 Global Omalizumab Biosimilars Revenue by Region (2024-2029)
2.2.4 Global Omalizumab Biosimilars Revenue Market Share by Region (2018-2029)
2.3 Global Omalizumab Biosimilars Sales Estimates and Forecasts 2018-2029
2.4 Global Omalizumab Biosimilars Sales by Region
2.4.1 Global Omalizumab Biosimilars Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Omalizumab Biosimilars Sales by Region (2018-2024)
2.4.3 Global Omalizumab Biosimilars Sales by Region (2024-2029)
2.4.4 Global Omalizumab Biosimilars Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Omalizumab Biosimilars Sales by Manufacturers
3.1.1 Global Omalizumab Biosimilars Sales by Manufacturers (2018-2024)
3.1.2 Global Omalizumab Biosimilars Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Omalizumab Biosimilars in 2022
3.2 Global Omalizumab Biosimilars Revenue by Manufacturers
3.2.1 Global Omalizumab Biosimilars Revenue by Manufacturers (2018-2024)
3.2.2 Global Omalizumab Biosimilars Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Omalizumab Biosimilars Revenue in 2022
3.3 Global Key Players of Omalizumab Biosimilars, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Omalizumab Biosimilars Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Omalizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Omalizumab Biosimilars, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Omalizumab Biosimilars, Product Offered and Application
3.8 Global Key Manufacturers of Omalizumab Biosimilars, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Omalizumab Biosimilars Sales by Type
4.1.1 Global Omalizumab Biosimilars Historical Sales by Type (2018-2024)
4.1.2 Global Omalizumab Biosimilars Forecasted Sales by Type (2024-2029)
4.1.3 Global Omalizumab Biosimilars Sales Market Share by Type (2018-2029)
4.2 Global Omalizumab Biosimilars Revenue by Type
4.2.1 Global Omalizumab Biosimilars Historical Revenue by Type (2018-2024)
4.2.2 Global Omalizumab Biosimilars Forecasted Revenue by Type (2024-2029)
4.2.3 Global Omalizumab Biosimilars Revenue Market Share by Type (2018-2029)
4.3 Global Omalizumab Biosimilars Price by Type
4.3.1 Global Omalizumab Biosimilars Price by Type (2018-2024)
4.3.2 Global Omalizumab Biosimilars Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Omalizumab Biosimilars Sales by Application
5.1.1 Global Omalizumab Biosimilars Historical Sales by Application (2018-2024)
5.1.2 Global Omalizumab Biosimilars Forecasted Sales by Application (2024-2029)
5.1.3 Global Omalizumab Biosimilars Sales Market Share by Application (2018-2029)
5.2 Global Omalizumab Biosimilars Revenue by Application
5.2.1 Global Omalizumab Biosimilars Historical Revenue by Application (2018-2024)
5.2.2 Global Omalizumab Biosimilars Forecasted Revenue by Application (2024-2029)
5.2.3 Global Omalizumab Biosimilars Revenue Market Share by Application (2018-2029)
5.3 Global Omalizumab Biosimilars Price by Application
5.3.1 Global Omalizumab Biosimilars Price by Application (2018-2024)
5.3.2 Global Omalizumab Biosimilars Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Omalizumab Biosimilars Market Size by Type
6.1.1 US & Canada Omalizumab Biosimilars Sales by Type (2018-2029)
6.1.2 US & Canada Omalizumab Biosimilars Revenue by Type (2018-2029)
6.2 US & Canada Omalizumab Biosimilars Market Size by Application
6.2.1 US & Canada Omalizumab Biosimilars Sales by Application (2018-2029)
6.2.2 US & Canada Omalizumab Biosimilars Revenue by Application (2018-2029)
6.3 US & Canada Omalizumab Biosimilars Market Size by Country
6.3.1 US & Canada Omalizumab Biosimilars Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Omalizumab Biosimilars Sales by Country (2018-2029)
6.3.3 US & Canada Omalizumab Biosimilars Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Omalizumab Biosimilars Market Size by Type
7.1.1 Europe Omalizumab Biosimilars Sales by Type (2018-2029)
7.1.2 Europe Omalizumab Biosimilars Revenue by Type (2018-2029)
7.2 Europe Omalizumab Biosimilars Market Size by Application
7.2.1 Europe Omalizumab Biosimilars Sales by Application (2018-2029)
7.2.2 Europe Omalizumab Biosimilars Revenue by Application (2018-2029)
7.3 Europe Omalizumab Biosimilars Market Size by Country
7.3.1 Europe Omalizumab Biosimilars Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Omalizumab Biosimilars Sales by Country (2018-2029)
7.3.3 Europe Omalizumab Biosimilars Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Omalizumab Biosimilars Market Size
8.1.1 China Omalizumab Biosimilars Sales (2018-2029)
8.1.2 China Omalizumab Biosimilars Revenue (2018-2029)
8.2 China Omalizumab Biosimilars Market Size by Application
8.2.1 China Omalizumab Biosimilars Sales by Application (2018-2029)
8.2.2 China Omalizumab Biosimilars Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Omalizumab Biosimilars Market Size by Type
9.1.1 Asia Omalizumab Biosimilars Sales by Type (2018-2029)
9.1.2 Asia Omalizumab Biosimilars Revenue by Type (2018-2029)
9.2 Asia Omalizumab Biosimilars Market Size by Application
9.2.1 Asia Omalizumab Biosimilars Sales by Application (2018-2029)
9.2.2 Asia Omalizumab Biosimilars Revenue by Application (2018-2029)
9.3 Asia Omalizumab Biosimilars Sales by Region
9.3.1 Asia Omalizumab Biosimilars Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Omalizumab Biosimilars Revenue by Region (2018-2029)
9.3.3 Asia Omalizumab Biosimilars Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Omalizumab Biosimilars Market Size by Type
10.1.1 Middle East, Africa and Latin America Omalizumab Biosimilars Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Omalizumab Biosimilars Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Omalizumab Biosimilars Market Size by Application
10.2.1 Middle East, Africa and Latin America Omalizumab Biosimilars Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Omalizumab Biosimilars Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Omalizumab Biosimilars Sales by Country
10.3.1 Middle East, Africa and Latin America Omalizumab Biosimilars Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Omalizumab Biosimilars Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Omalizumab Biosimilars Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Overview
11.1.3 Roche Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Roche Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Roche Recent Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis Overview
11.2.3 Novartis Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Novartis Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Novartis Recent Developments
11.3 Glenmark Pharmaceuticals
11.3.1 Glenmark Pharmaceuticals Company Information
11.3.2 Glenmark Pharmaceuticals Overview
11.3.3 Glenmark Pharmaceuticals Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Glenmark Pharmaceuticals Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Glenmark Pharmaceuticals Recent Developments
11.4 Selexis
11.4.1 Selexis Company Information
11.4.2 Selexis Overview
11.4.3 Selexis Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Selexis Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Selexis Recent Developments
11.5 Generium
11.5.1 Generium Company Information
11.5.2 Generium Overview
11.5.3 Generium Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Generium Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Generium Recent Developments
11.6 CuraTeQ
11.6.1 CuraTeQ Company Information
11.6.2 CuraTeQ Overview
11.6.3 CuraTeQ Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 CuraTeQ Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 CuraTeQ Recent Developments
11.7 Celltrion Healthcare
11.7.1 Celltrion Healthcare Company Information
11.7.2 Celltrion Healthcare Overview
11.7.3 Celltrion Healthcare Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Celltrion Healthcare Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Celltrion Healthcare Recent Developments
11.8 Alvotech
11.8.1 Alvotech Company Information
11.8.2 Alvotech Overview
11.8.3 Alvotech Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Alvotech Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Alvotech Recent Developments
11.9 BiosanaPharma
11.9.1 BiosanaPharma Company Information
11.9.2 BiosanaPharma Overview
11.9.3 BiosanaPharma Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 BiosanaPharma Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 BiosanaPharma Recent Developments
11.10 Mabpharm
11.10.1 Mabpharm Company Information
11.10.2 Mabpharm Overview
11.10.3 Mabpharm Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Mabpharm Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Mabpharm Recent Developments
11.11 CSPC Pharmaceutical Group
11.11.1 CSPC Pharmaceutical Group Company Information
11.11.2 CSPC Pharmaceutical Group Overview
11.11.3 CSPC Pharmaceutical Group Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 CSPC Pharmaceutical Group Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 CSPC Pharmaceutical Group Recent Developments
11.12 Biomabs
11.12.1 Biomabs Company Information
11.12.2 Biomabs Overview
11.12.3 Biomabs Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 Biomabs Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Biomabs Recent Developments
11.13 HisunPharm
11.13.1 HisunPharm Company Information
11.13.2 HisunPharm Overview
11.13.3 HisunPharm Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2018-2024)
11.13.4 HisunPharm Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 HisunPharm Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Omalizumab Biosimilars Industry Chain Analysis
12.2 Omalizumab Biosimilars Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Omalizumab Biosimilars Production Mode & Process
12.4 Omalizumab Biosimilars Sales and Marketing
12.4.1 Omalizumab Biosimilars Sales Channels
12.4.2 Omalizumab Biosimilars Distributors
12.5 Omalizumab Biosimilars Customers
13 Market Dynamics
13.1 Omalizumab Biosimilars Industry Trends
13.2 Omalizumab Biosimilars Market Drivers
13.3 Omalizumab Biosimilars Market Challenges
13.4 Omalizumab Biosimilars Market Restraints
14 Key Findings in The Global Omalizumab Biosimilars Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Omalizumab Biosimilars Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of 150 mg/mL
Table 3. Major Manufacturers of 75 mg/0.5 mL
Table 4. Global Omalizumab Biosimilars Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global Omalizumab Biosimilars Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Omalizumab Biosimilars Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Omalizumab Biosimilars Revenue by Region (2024-2029) & (US$ Million)
Table 8. Global Omalizumab Biosimilars Revenue Market Share by Region (2018-2024)
Table 9. Global Omalizumab Biosimilars Revenue Market Share by Region (2024-2029)
Table 10. Global Omalizumab Biosimilars Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global Omalizumab Biosimilars Sales by Region (2018-2024) & (K Units)
Table 12. Global Omalizumab Biosimilars Sales by Region (2024-2029) & (K Units)
Table 13. Global Omalizumab Biosimilars Sales Market Share by Region (2018-2024)
Table 14. Global Omalizumab Biosimilars Sales Market Share by Region (2024-2029)
Table 15. Global Omalizumab Biosimilars Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global Omalizumab Biosimilars Sales Share by Manufacturers (2018-2024)
Table 17. Global Omalizumab Biosimilars Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Omalizumab Biosimilars Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of Omalizumab Biosimilars, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. Omalizumab Biosimilars Price by Manufacturers 2018-2024 (USD/Unit)
Table 21. Global Omalizumab Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Omalizumab Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Omalizumab Biosimilars as of 2022)
Table 23. Global Key Manufacturers of Omalizumab Biosimilars, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Omalizumab Biosimilars, Product Offered and Application
Table 25. Global Key Manufacturers of Omalizumab Biosimilars, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Omalizumab Biosimilars Sales by Type (2018-2024) & (K Units)
Table 28. Global Omalizumab Biosimilars Sales by Type (2024-2029) & (K Units)
Table 29. Global Omalizumab Biosimilars Sales Share by Type (2018-2024)
Table 30. Global Omalizumab Biosimilars Sales Share by Type (2024-2029)
Table 31. Global Omalizumab Biosimilars Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Omalizumab Biosimilars Revenue by Type (2024-2029) & (US$ Million)
Table 33. Global Omalizumab Biosimilars Revenue Share by Type (2018-2024)
Table 34. Global Omalizumab Biosimilars Revenue Share by Type (2024-2029)
Table 35. Omalizumab Biosimilars Price by Type (2018-2024) & (USD/Unit)
Table 36. Global Omalizumab Biosimilars Price Forecast by Type (2024-2029) & (USD/Unit)
Table 37. Global Omalizumab Biosimilars Sales by Application (2018-2024) & (K Units)
Table 38. Global Omalizumab Biosimilars Sales by Application (2024-2029) & (K Units)
Table 39. Global Omalizumab Biosimilars Sales Share by Application (2018-2024)
Table 40. Global Omalizumab Biosimilars Sales Share by Application (2024-2029)
Table 41. Global Omalizumab Biosimilars Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Omalizumab Biosimilars Revenue by Application (2024-2029) & (US$ Million)
Table 43. Global Omalizumab Biosimilars Revenue Share by Application (2018-2024)
Table 44. Global Omalizumab Biosimilars Revenue Share by Application (2024-2029)
Table 45. Omalizumab Biosimilars Price by Application (2018-2024) & (USD/Unit)
Table 46. Global Omalizumab Biosimilars Price Forecast by Application (2024-2029) & (USD/Unit)
Table 47. US & Canada Omalizumab Biosimilars Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada Omalizumab Biosimilars Sales by Type (2024-2029) & (K Units)
Table 49. US & Canada Omalizumab Biosimilars Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada Omalizumab Biosimilars Revenue by Type (2024-2029) & (US$ Million)
Table 51. US & Canada Omalizumab Biosimilars Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada Omalizumab Biosimilars Sales by Application (2024-2029) & (K Units)
Table 53. US & Canada Omalizumab Biosimilars Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada Omalizumab Biosimilars Revenue by Application (2024-2029) & (US$ Million)
Table 55. US & Canada Omalizumab Biosimilars Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. US & Canada Omalizumab Biosimilars Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada Omalizumab Biosimilars Revenue by Country (2024-2029) & (US$ Million)
Table 58. US & Canada Omalizumab Biosimilars Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada Omalizumab Biosimilars Sales by Country (2024-2029) & (K Units)
Table 60. Europe Omalizumab Biosimilars Sales by Type (2018-2024) & (K Units)
Table 61. Europe Omalizumab Biosimilars Sales by Type (2024-2029) & (K Units)
Table 62. Europe Omalizumab Biosimilars Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe Omalizumab Biosimilars Revenue by Type (2024-2029) & (US$ Million)
Table 64. Europe Omalizumab Biosimilars Sales by Application (2018-2024) & (K Units)
Table 65. Europe Omalizumab Biosimilars Sales by Application (2024-2029) & (K Units)
Table 66. Europe Omalizumab Biosimilars Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe Omalizumab Biosimilars Revenue by Application (2024-2029) & (US$ Million)
Table 68. Europe Omalizumab Biosimilars Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 69. Europe Omalizumab Biosimilars Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe Omalizumab Biosimilars Revenue by Country (2024-2029) & (US$ Million)
Table 71. Europe Omalizumab Biosimilars Sales by Country (2018-2024) & (K Units)
Table 72. Europe Omalizumab Biosimilars Sales by Country (2024-2029) & (K Units)
Table 73. China Omalizumab Biosimilars Sales by Type (2018-2024) & (K Units)
Table 74. China Omalizumab Biosimilars Sales by Type (2024-2029) & (K Units)
Table 75. China Omalizumab Biosimilars Revenue by Type (2018-2024) & (US$ Million)
Table 76. China Omalizumab Biosimilars Revenue by Type (2024-2029) & (US$ Million)
Table 77. China Omalizumab Biosimilars Sales by Application (2018-2024) & (K Units)
Table 78. China Omalizumab Biosimilars Sales by Application (2024-2029) & (K Units)
Table 79. China Omalizumab Biosimilars Revenue by Application (2018-2024) & (US$ Million)
Table 80. China Omalizumab Biosimilars Revenue by Application (2024-2029) & (US$ Million)
Table 81. Asia Omalizumab Biosimilars Sales by Type (2018-2024) & (K Units)
Table 82. Asia Omalizumab Biosimilars Sales by Type (2024-2029) & (K Units)
Table 83. Asia Omalizumab Biosimilars Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia Omalizumab Biosimilars Revenue by Type (2024-2029) & (US$ Million)
Table 85. Asia Omalizumab Biosimilars Sales by Application (2018-2024) & (K Units)
Table 86. Asia Omalizumab Biosimilars Sales by Application (2024-2029) & (K Units)
Table 87. Asia Omalizumab Biosimilars Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia Omalizumab Biosimilars Revenue by Application (2024-2029) & (US$ Million)
Table 89. Asia Omalizumab Biosimilars Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 90. Asia Omalizumab Biosimilars Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia Omalizumab Biosimilars Revenue by Region (2024-2029) & (US$ Million)
Table 92. Asia Omalizumab Biosimilars Sales by Region (2018-2024) & (K Units)
Table 93. Asia Omalizumab Biosimilars Sales by Region (2024-2029) & (K Units)
Table 94. Middle East, Africa and Latin America Omalizumab Biosimilars Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America Omalizumab Biosimilars Sales by Type (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Omalizumab Biosimilars Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America Omalizumab Biosimilars Revenue by Type (2024-2029) & (US$ Million)
Table 98. Middle East, Africa and Latin America Omalizumab Biosimilars Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America Omalizumab Biosimilars Sales by Application (2024-2029) & (K Units)
Table 100. Middle East, Africa and Latin America Omalizumab Biosimilars Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Omalizumab Biosimilars Revenue by Application (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America Omalizumab Biosimilars Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 103. Middle East, Africa and Latin America Omalizumab Biosimilars Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Omalizumab Biosimilars Revenue by Country (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America Omalizumab Biosimilars Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Omalizumab Biosimilars Sales by Country (2024-2029) & (K Units)
Table 107. Roche Company Information
Table 108. Roche Description and Major Businesses
Table 109. Roche Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 110. Roche Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Roche Recent Developments
Table 112. Novartis Company Information
Table 113. Novartis Description and Major Businesses
Table 114. Novartis Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 115. Novartis Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Novartis Recent Developments
Table 117. Glenmark Pharmaceuticals Company Information
Table 118. Glenmark Pharmaceuticals Description and Major Businesses
Table 119. Glenmark Pharmaceuticals Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 120. Glenmark Pharmaceuticals Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Glenmark Pharmaceuticals Recent Developments
Table 122. Selexis Company Information
Table 123. Selexis Description and Major Businesses
Table 124. Selexis Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 125. Selexis Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Selexis Recent Developments
Table 127. Generium Company Information
Table 128. Generium Description and Major Businesses
Table 129. Generium Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 130. Generium Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Generium Recent Developments
Table 132. CuraTeQ Company Information
Table 133. CuraTeQ Description and Major Businesses
Table 134. CuraTeQ Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 135. CuraTeQ Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. CuraTeQ Recent Developments
Table 137. Celltrion Healthcare Company Information
Table 138. Celltrion Healthcare Description and Major Businesses
Table 139. Celltrion Healthcare Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 140. Celltrion Healthcare Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Celltrion Healthcare Recent Developments
Table 142. Alvotech Company Information
Table 143. Alvotech Description and Major Businesses
Table 144. Alvotech Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 145. Alvotech Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Alvotech Recent Developments
Table 147. BiosanaPharma Company Information
Table 148. BiosanaPharma Description and Major Businesses
Table 149. BiosanaPharma Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 150. BiosanaPharma Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. BiosanaPharma Recent Developments
Table 152. Mabpharm Company Information
Table 153. Mabpharm Description and Major Businesses
Table 154. Mabpharm Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 155. Mabpharm Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Mabpharm Recent Developments
Table 157. CSPC Pharmaceutical Group Company Information
Table 158. CSPC Pharmaceutical Group Description and Major Businesses
Table 159. CSPC Pharmaceutical Group Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 160. CSPC Pharmaceutical Group Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. CSPC Pharmaceutical Group Recent Developments
Table 162. Biomabs Company Information
Table 163. Biomabs Description and Major Businesses
Table 164. Biomabs Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 165. Biomabs Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. Biomabs Recent Developments
Table 167. HisunPharm Company Information
Table 168. HisunPharm Description and Major Businesses
Table 169. HisunPharm Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 170. HisunPharm Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. HisunPharm Recent Developments
Table 172. Key Raw Materials Lists
Table 173. Raw Materials Key Suppliers Lists
Table 174. Omalizumab Biosimilars Distributors List
Table 175. Omalizumab Biosimilars Customers List
Table 176. Omalizumab Biosimilars Market Trends
Table 177. Omalizumab Biosimilars Market Drivers
Table 178. Omalizumab Biosimilars Market Challenges
Table 179. Omalizumab Biosimilars Market Restraints
Table 180. Research Programs/Design for This Report
Table 181. Key Data Information from Secondary Sources
Table 182. Key Data Information from Primary Sources
List of Figures
Figure 1. Omalizumab Biosimilars Product Picture
Figure 2. Global Omalizumab Biosimilars Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Omalizumab Biosimilars Market Share by Type in 2022 & 2029
Figure 4. 150 mg/mL Product Picture
Figure 5. 75 mg/0.5 mL Product Picture
Figure 6. Global Omalizumab Biosimilars Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global Omalizumab Biosimilars Market Share by Application in 2022 & 2029
Figure 8. Persistent Asthma
Figure 9. Nasal Polyps
Figure 10. Chronic Idiopathic Urticaria
Figure 11. Omalizumab Biosimilars Report Years Considered
Figure 12. Global Omalizumab Biosimilars Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Omalizumab Biosimilars Revenue 2018-2029 (US$ Million)
Figure 14. Global Omalizumab Biosimilars Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 15. Global Omalizumab Biosimilars Revenue Market Share by Region (2018-2029)
Figure 16. Global Omalizumab Biosimilars Sales 2018-2029 ((K Units)
Figure 17. Global Omalizumab Biosimilars Sales Market Share by Region (2018-2029)
Figure 18. US & Canada Omalizumab Biosimilars Sales YoY (2018-2029) & (K Units)
Figure 19. US & Canada Omalizumab Biosimilars Revenue YoY (2018-2029) & (US$ Million)
Figure 20. Europe Omalizumab Biosimilars Sales YoY (2018-2029) & (K Units)
Figure 21. Europe Omalizumab Biosimilars Revenue YoY (2018-2029) & (US$ Million)
Figure 22. China Omalizumab Biosimilars Sales YoY (2018-2029) & (K Units)
Figure 23. China Omalizumab Biosimilars Revenue YoY (2018-2029) & (US$ Million)
Figure 24. Asia (excluding China) Omalizumab Biosimilars Sales YoY (2018-2029) & (K Units)
Figure 25. Asia (excluding China) Omalizumab Biosimilars Revenue YoY (2018-2029) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Omalizumab Biosimilars Sales YoY (2018-2029) & (K Units)
Figure 27. Middle East, Africa and Latin America Omalizumab Biosimilars Revenue YoY (2018-2029) & (US$ Million)
Figure 28. The Omalizumab Biosimilars Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 29. The Top 5 and 10 Largest Manufacturers of Omalizumab Biosimilars in the World: Market Share by Omalizumab Biosimilars Revenue in 2022
Figure 30. Global Omalizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 31. Global Omalizumab Biosimilars Sales Market Share by Type (2018-2029)
Figure 32. Global Omalizumab Biosimilars Revenue Market Share by Type (2018-2029)
Figure 33. Global Omalizumab Biosimilars Sales Market Share by Application (2018-2029)
Figure 34. Global Omalizumab Biosimilars Revenue Market Share by Application (2018-2029)
Figure 35. US & Canada Omalizumab Biosimilars Sales Market Share by Type (2018-2029)
Figure 36. US & Canada Omalizumab Biosimilars Revenue Market Share by Type (2018-2029)
Figure 37. US & Canada Omalizumab Biosimilars Sales Market Share by Application (2018-2029)
Figure 38. US & Canada Omalizumab Biosimilars Revenue Market Share by Application (2018-2029)
Figure 39. US & Canada Omalizumab Biosimilars Revenue Share by Country (2018-2029)
Figure 40. US & Canada Omalizumab Biosimilars Sales Share by Country (2018-2029)
Figure 41. U.S. Omalizumab Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 42. Canada Omalizumab Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 43. Europe Omalizumab Biosimilars Sales Market Share by Type (2018-2029)
Figure 44. Europe Omalizumab Biosimilars Revenue Market Share by Type (2018-2029)
Figure 45. Europe Omalizumab Biosimilars Sales Market Share by Application (2018-2029)
Figure 46. Europe Omalizumab Biosimilars Revenue Market Share by Application (2018-2029)
Figure 47. Europe Omalizumab Biosimilars Revenue Share by Country (2018-2029)
Figure 48. Europe Omalizumab Biosimilars Sales Share by Country (2018-2029)
Figure 49. Germany Omalizumab Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 50. France Omalizumab Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 51. U.K. Omalizumab Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 52. Italy Omalizumab Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 53. Russia Omalizumab Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 54. China Omalizumab Biosimilars Sales Market Share by Type (2018-2029)
Figure 55. China Omalizumab Biosimilars Revenue Market Share by Type (2018-2029)
Figure 56. China Omalizumab Biosimilars Sales Market Share by Application (2018-2029)
Figure 57. China Omalizumab Biosimilars Revenue Market Share by Application (2018-2029)
Figure 58. Asia Omalizumab Biosimilars Sales Market Share by Type (2018-2029)
Figure 59. Asia Omalizumab Biosimilars Revenue Market Share by Type (2018-2029)
Figure 60. Asia Omalizumab Biosimilars Sales Market Share by Application (2018-2029)
Figure 61. Asia Omalizumab Biosimilars Revenue Market Share by Application (2018-2029)
Figure 62. Asia Omalizumab Biosimilars Revenue Share by Region (2018-2029)
Figure 63. Asia Omalizumab Biosimilars Sales Share by Region (2018-2029)
Figure 64. Japan Omalizumab Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 65. South Korea Omalizumab Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 66. China Taiwan Omalizumab Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 67. Southeast Asia Omalizumab Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 68. India Omalizumab Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 69. Middle East, Africa and Latin America Omalizumab Biosimilars Sales Market Share by Type (2018-2029)
Figure 70. Middle East, Africa and Latin America Omalizumab Biosimilars Revenue Market Share by Type (2018-2029)
Figure 71. Middle East, Africa and Latin America Omalizumab Biosimilars Sales Market Share by Application (2018-2029)
Figure 72. Middle East, Africa and Latin America Omalizumab Biosimilars Revenue Market Share by Application (2018-2029)
Figure 73. Middle East, Africa and Latin America Omalizumab Biosimilars Revenue Share by Country (2018-2029)
Figure 74. Middle East, Africa and Latin America Omalizumab Biosimilars Sales Share by Country (2018-2029)
Figure 75. Brazil Omalizumab Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 76. Mexico Omalizumab Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 77. Turkey Omalizumab Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 78. Israel Omalizumab Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 79. GCC Countries Omalizumab Biosimilars Revenue (2018-2029) & (US$ Million)
Figure 80. Omalizumab Biosimilars Value Chain
Figure 81. Omalizumab Biosimilars Production Process
Figure 82. Channels of Distribution
Figure 83. Distributors Profiles
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries